Wall Street analyst estimates for Ainos, Inc. (AIMD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-03 | $-0.62 | ||
| 2026-05-13 | $-0.41 | ||
| 2026-03-30 | $-0.85 | ||
| 2025-11-13 | $-0.64 | ||
| 2025-08-13 | $-0.99 | ||
| 2025-05-12 | $-1.05 | ||
| 2025-03-07 | $-1.30 | ||
| 2024-11-06 | $-1.65 |
Valuation Ratios
| Price / Book | 2.82 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $250928 | $77724 | $11731 | $16563 | $594563 | $3.5M | $122112 | $20729 | $124157 |
| Cost of Revenue | $25956 | $60316 | $64877 | $8772 | $11277 | $184181 | $2.1M | $375845 | $52595 | $4.8M |
| Gross Profit | -$25956 | $190612 | $12847 | $2959 | $5286 | $410382 | $1.4M | -$253733 | -$31866 | -$4.7M |
| Research & Development | 0 | 0 | $32591 | $52510 | $389 | $1.9M | $6.8M | $7.3M | $8.4M | $7.7M |
| Selling, General & Admin | $667111 | $770375 | $1.3M | $1.5M | $1.4M | $2.4M | $8.5M | $5.6M | $5.4M | $1.6M |
| Operating Expenses | $667111 | $770375 | $1.3M | $1.6M | $1.4M | $4.3M | $15.4M | $13.0M | $13.8M | $9.3M |
| Operating Income | -$667111 | -$579763 | -$1.3M | -$1.6M | -$1.4M | -$3.9M | -$14.0M | -$13.2M | -$13.8M | -$14.0M |
| EBITDA | -$641155 | -$539773 | -$1.3M | -$1.6M | -$1.4M | -$1.8M | -$9.1M | -$8.8M | -$9.4M | -$9.3M |
| Interest Expense | $2871 | $37612 | $3963 | $885 | $10188 | $18689 | $53528 | $144193 | $616467 | $711903 |
| Pre-tax Income | -$669982 | -$617375 | -$1.3M | -$1.6M | -$1.5M | -$3.9M | -$14.0M | -$13.8M | -$14.9M | -$14.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | $16141 | 0 | $800 | $800 | $800 |
| Net Income | -$669982 | -$617375 | -$1.3M | -$1.6M | -$1.5M | -$3.9M | -$14.0M | -$13.8M | -$14.9M | -$14.8M |
| EPS | $-0.50 | $-0.41 | $-0.56 | $-0.74 | $-2.69 | $-2.59 | $-5.14 | $-3.36 | $-1.56 | $-3.46 |
| EPS (Diluted) | $-0.50 | $-0.41 | $-0.56 | $-0.74 | $-2.69 | $-2.59 | $-5.14 | $-3.36 | $-1.56 | $-3.46 |
| Shares Outstanding (Diluted) | $1.3M | $1.5M | $2.4M | $2.1M | $543079 | $1.5M | $2.7M | $4.1M | $9.5M | $4.3M |
Price
| Price | $1.38 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADTX · ANL · ATHA · BLRX · DARE · FBLG · GOVX
Explore sector: Healthcare · Biotechnology
More sections of AIMD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks